Literature DB >> 25029237

Evaluating mortality in an intensive care unit requires extended survival models.

Martin Wolkewitz, Harriet Sommer.   

Abstract

Entities:  

Mesh:

Year:  2014        PMID: 25029237      PMCID: PMC4057513          DOI: 10.1186/cc13757

Source DB:  PubMed          Journal:  Crit Care        ISSN: 1364-8535            Impact factor:   9.097


× No keyword cloud information.

In a recent issue of Critical Care, we read with great interest that admission at nighttime is associated with poor outcomes in intensive care units (ICUs) [1]. However, Ju and colleagues showed cumulative survival plots predicting a poor survival in the ICU of less than 20% after 2,000 ICU-hours for patients for both groups (nighttime or office time) despite the fact that 148 out of 175 patients (84.6%) survived the ICU (nighttime group) and patients admitted during office time have even an ICU survival of 96.4%. These large discrepancies are very confusing for the reader. We argue that this result is subject to a common type of survival bias [2], which we explain as follows. A fundamental assumption for calculating Kaplan-Meier survival curves is that censoring is non-informative in the sense that the hazard of death remains unchanged when a censoring event occurs. Presumably, the authors treated discharged patients as censored (displayed as crosses in their figures [1]). It is obvious that this assumption does not hold since discharged patients are usually in a better health condition than patients who stay in the ICU. This wrong assumption led to artificially reduced survival plots. The statistical solution for this is to treat discharge as a competing event for death in the ICU [2], [3] since the cumulative probability of death in the ICU depends not only on the ICU death hazard rate but also on the discharge rate. Evaluating ICU mortality requires advanced statistical methods. Incorrect results may lead to wrong conclusions for clinicians and finally impact patient care. For that reason, it is crucial to have adequate and valid predictions for this important clinical outcome in hospital epidemiology.

Authors’ response

Min-Jie Ju, Jian-Feng Luo, and Zhe Luo

We were delighted to have the opportunity to receive the advice of Wolkewitz and Sommer. Honestly, their criticism was constructive and helped us to consolidate the results of our study [1]. Hence, we might set a competing risks model to improve our analysis. Survival analysis is a good tool when researchers take into account the time until an event occurs and the censored data. One of the common mistakes when applying survival analysis is not to include the censored data [4]. The primary outcome of our study was the ICU mortality, not the hospital mortality. The definition of ‘event’ was that patients died during their stay in the ICU. If the patients were alive after they were discharged from the ICU, they were censored (left-censored). We agree with Wolkewitz and Sommer that discharged patients might be in a better health condition. Therefore, we also applied survival analysis in the propensity score matching cohort where the discharged ratio were balance distributed between nighttime and office hours (Table 1). Thus, the censoring bias was minimized and would not influence the primary result.
Table 1

Comparison of discharged ratio between nighttime and office hours admissions in 1:1 propensity score matching group

 
Intensive care unit outcome
P value a
 Discharged (alive)Dead 
Office hours
155
20
0.272
Nighttime14827 

aChi-squared test.

Comparison of discharged ratio between nighttime and office hours admissions in 1:1 propensity score matching group aChi-squared test. As for large discrepancies between the cumulative ICU survival after 2,000 ICU-hours and ICU survival probability, we think they were conceived differently. The former meant a property of any patient’s survival time longer than t time, and the latter meant the ratio of the number of patients who were alive during ICU stay to the total number of patients. Accordingly, the analysis in our study had enough power to yield a credible result.

Abbreviations

ICU: Intensive care unit.

Competing interests

The authors declare that they have no competing interests.
  4 in total

Review 1.  Competing risks in epidemiology: possibilities and pitfalls.

Authors:  Per Kragh Andersen; Ronald B Geskus; Theo de Witte; Hein Putter
Journal:  Int J Epidemiol       Date:  2012-01-09       Impact factor: 7.196

2.  Survival analysis: part 15 of a series on evaluation of scientific publications.

Authors:  Isabella Zwiener; Maria Blettner; Gerhard Hommel
Journal:  Dtsch Arztebl Int       Date:  2011-03-11       Impact factor: 5.594

3.  Effect of admission time on mortality in an intensive care unit in Mainland China: a propensity score matching analysis.

Authors:  Min-Jie Ju; Guo-Wei Tu; Yan Han; Hong-Yu He; Yi-Zhou He; Hai-Lei Mao; Zhao-Guang Wu; Yi-Qing Yin; Jian-Feng Luo; Du-Ming Zhu; Zhe Luo; Zhang-Gang Xue
Journal:  Crit Care       Date:  2013-10-10       Impact factor: 9.097

4.  Risk factors for the development of nosocomial pneumonia and mortality on intensive care units: application of competing risks models.

Authors:  Martin Wolkewitz; Ralf Peter Vonberg; Hajo Grundmann; Jan Beyersmann; Petra Gastmeier; Sina Bärwolff; Christine Geffers; Michael Behnke; Henning Rüden; Martin Schumacher
Journal:  Crit Care       Date:  2008-04-02       Impact factor: 9.097

  4 in total
  2 in total

1.  Predictors of 6-month health utility outcomes in survivors of acute respiratory distress syndrome.

Authors:  Samuel M Brown; Emily Wilson; Angela P Presson; Chong Zhang; Victor D Dinglas; Tom Greene; Ramona O Hopkins; Dale M Needham
Journal:  Thorax       Date:  2016-07-20       Impact factor: 9.139

2.  Statistical Analysis of Clinical COVID-19 Data: A Concise Overview of Lessons Learned, Common Errors and How to Avoid Them.

Authors:  Martin Wolkewitz; Jerome Lambert; Maja von Cube; Lars Bugiera; Marlon Grodd; Derek Hazard; Nicole White; Adrian Barnett; Klaus Kaier
Journal:  Clin Epidemiol       Date:  2020-09-03       Impact factor: 4.790

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.